Browsing by Subject "Platelet function tests"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Restricted
    Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?
    (2004-12-16) González-Conejero Hilla, Rocío; Rivera Pozo, José; Corral de la Calle, Javier; Acuña, Carmen; Vicente, Vincente; Guerrero López, José Antonio; Medicina Interna; Facultad de Medicina
    Background and Purpose— The widespread use of aspirin requires clarification of the aspirin resistance phenomenon. Most studies on this field are focused on patients which may affect the action of aspirin. Methods— We evaluated the biological efficacy of aspirin in healthy subjects. Results— Agonist–induced platelet aggregation was fully abrogated by 100 mg of aspirin in all individuals. By contrast, with the platelet function analyzer-100 device, 33.3% of the subjects displayed no response. This failure was overcome by 500 mg or by in vitro treatment of blood with 30 μmol/L acetylsalicylic acid. Intake of 100 mg of aspirin efficiently reduced by 75% the level of 11-dehydro thromboxane B2 (11-dTxB2) in all cases. However, variability on the pre-aspirin level (range 72.4 to 625.9 ng/mmol creatinine) led to substantial differences in the residual amount of the metabolite between subjects treated with aspirin (range 12.9 to 118.0 ng/mmol creatinine). Finally, there was no influence of platelet glycoprotein IIb/IIIa (Pro33Leu), platelet glycoprotein Ia/IIa, (C807T), and FXIII (Val34Leu) polymorphisms on the efficacy of aspirin. However, the cyclooxygenase (Cox)-1 50T allele associated with higher level of 11-dTxB2, both before and after aspirin. Moreover, the Cox-2 −765C variant displayed a slightly higher reduction in 11-dTxB2 level on treatment with aspirin. Conclusions— Our findings suggest that full resistance of healthy subjects to aspirin is rather unlikely. However, differences in aspirin absorption, or pharmacokinetic, or other unrecognized factors may lead to lack of effect of low dose of aspirin in some subjects when using tests like platelet function analyzer-100. Whether Cox polymorphisms are thrombotic risk factor for patients under aspirin will require further research.
  • Thumbnail Image
    Publication
    Restricted
    Bleeding risk prediction in patients with dual antiplatelet therapy undergoing coronary artery bypass grafting surgery using a rapid point-of-care platelet function test
    (Lippincott, Williams & Wilkins, 2018-12-11) Tello Montoliu, Antonio; Albaladejo, Paula; Taboada, Rubén; Albacete, Carlos L.; Arribas, José María; Jara, Rubén; Veliz, Andrea; López García, Cecilia; Cánovas López, Sergio; Valdés, Mariano; Rivera Caravaca, José Miguel; Marín, Francisco; Hernández Romero, Diana; Cirugía, Pediatría y Obstetricia y Ginecología